Sanofi and Recursion Reimagine Drug Discovery with AI
kshameer · x · 2026-07-10
This piece explores how Sanofi and Recursion Pharma are leveraging AI to redesign the drug discovery process, focusing on practical applications of AI in pharmaceutical R&D.
The post links to a related article, emphasizing the collaboration and methodological restructuring by the two companies in drug discovery, rather than just discussing concepts.
More from Companies & People
- This week’s NYC AI events include Cerebras, Google DeepMind, and a Physical AI hackathon — round · 2026-07-21
- Opendoor CEO shares a raw turnaround playbook in a rare live interview — morganb · 2026-07-21
- A market map tracks outpatient healthcare agentic AI across front, back and mid office — HealthcareAIGuy · 2026-07-21
- FutureCaribbean’s Buildathon offers $50K, H200 compute, and an NYSE pitch — HeyAmit_ · 2026-07-21
- Reliability is a discipline, not a one-time milestone for engineering teams — rseroter · 2026-07-21
- Cloud giants are winning enterprise agentic AI as enterprises buy trust, not features — DavidLinthicum · 2026-07-21